I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Trung Huynh maintained a Buy rating on Johnson & Johnson (JNJ) with a $287 price target. The stock closed at $267.08. Huynh, known for his strong track record, covers the healthcare sector. Additionally, HSBC also issued a Buy rating for JNJ with a higher target of $320. Overall analyst consensus remains a Strong Buy, with an average target of $287.59, indicating significant upside potential.
RBC Capital analyst Trung Huynh maintained a Buy rating on Johnson & Johnson on September 9 and set a price target of $287.00. The company’s shares closed yesterday at $267.08.
Huynh covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and AbbVie. According to TipRanks, Huynh has an average return of 22.2% and a 74.66% success rate on recommended stocks.
Currently, the analyst consensus on Johnson & Johnson is a Strong Buy with an average price target of $287.59, a 7.68% upside from current levels. In a report released yesterday, HSBC also maintained a Buy rating on the stock with a $320.00 price target.